Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

120.96 -5.77 (-4.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera Inc

< Previous 1 2 3 4 5 6 Next >
Natera to Present New Renasight Data at ASN Kidney Week 2024
From Natera, Inc.
Via Business Wire
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
From Natera, Inc.
Via Business Wire
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
From Natera, Inc.
Via Business Wire
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Friday Morning
Via Investor Brand Network
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
From Natera, Inc.
Via Business Wire
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
From Natera, Inc.
Via Business Wire
Natera Reports Second Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Natera, Inc.
Via Business Wire
Natera to Report its Second Quarter 2024 Results on August 8, 2024
From Natera, Inc.
Via Business Wire
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
From Natera, Inc.
Via Business Wire
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
From Natera, Inc.
Via Business Wire
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
Via MarketBeat
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
From Natera, Inc.
Via Business Wire
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Natera, Inc.
Via Business Wire
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
From Natera, Inc.
Via Business Wire
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
From Natera, Inc.
Via Business Wire
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
From Natera, Inc.
Via Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Natera Reports First Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
From Natera, Inc.
Via Business Wire
Natera to Report its First Quarter 2024 Results on May 9
From Natera, Inc.
Via Business Wire
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
From Natera, Inc.
Via Business Wire
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
From Natera, Inc.
Via Business Wire
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
From Natera, Inc.
Via Business Wire
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
From Natera, Inc.
Via Business Wire
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
From Natera, Inc.
Via Business Wire
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
From Natera, Inc.
Via Business Wire
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.